

Cancer is detected **too late**

10M


cancer deaths per year globally¹



1 in 5 diagnosed with cancer in their lifetime¹

Cancer is a thief. It robs us of our family members, of our comfort, of once-in-a-lifetime opportunities. But what if there were a way to reduce cancer deaths by half in the next 25 years?

This is the future Exact Sciences works toward every day. **Because we believe it's possible.**



We're changing lives, **together**

Exact Sciences is strategically positioned to support patients and providers.

4M+

people tested in 2023² in over 120 countries

6,500+

global employees²

9

research and development centers and labs²

(5 in Wisconsin, 2 in California, 1 in Arizona, 1 in Massachusetts, 1 in Germany, 1 in United Kingdom)

40+

global office locations

Our global team, advanced capabilities, infrastructure, and dedication to taking on the impossible fuel our mission.

We are continually innovating and combining scientific rigor with an open-minded approach to deliver the next big thing.

Supporting patients before, during and after diagnosis

From hereditary cancer testing and earlier cancer screenings to treatment guidance and therapy selection, we aim to offer a comprehensive suite of tests that enables the delivery of personalized care.

Note: Pipeline tests are not available for commercial use. Availability of commercial tests outside of the US varies by country.



Cologuard® (Screening)

Cologuard is a stool DNA-based test for colorectal cancer screening for average-risk patients 45 and older.³ It is effective, non-invasive and FDA approved. Cologuard is a convenient option that patients can use in the privacy of their own homes, with no special prep, time off or changes in diet or medication necessary. Cologuard finds 92% of colon cancers, even in early stages.³ Cologuard is not for high-risk individuals.

Oncoguard® Liver (Surveillance)

The Oncoguard Liver solution was designed with the hope of bringing better outcomes to more people at risk of Hepatocellular Carcinoma (HCC), the most common form of liver cancer. The sophisticated, yet simple, blood test is for adults with liver cirrhosis and/or chronic hepatitis B (HBV) who are at risk for HCC and is designed for high performance to enable early-stage detection.⁴

Riskguard™ (Hereditary Cancer)

The Riskguard hereditary cancer test is a 32-gene Next Generation Sequencing test for those who want to understand their risk of developing inherited forms of cancer, why cancer may be common in their family, and their screening options. The test identifies germline (inherited) variants that may impact clinical decision-making in breast, prostate, colorectal, ovarian, endometrial, kidney, endocrine, pancreatic, gastric, and melanoma cancers.

Oncotype DX® (Prognosis & Treatment Guidance)

Every cancer is unique and affects each diagnosed person differently based on the individual biology of their disease. To address this diversity and make cancer care smarter, our Oncotype DX diagnostic portfolio delivers clinically relevant genomic intelligence specific to the individual biology of a patient's tumor. This additional genomic insight helps physicians optimize treatment decisions for breast and colon cancers.

OncoExTra® (Therapy Selection)

The OncoExTra test detects alterations in genes and provides a complete molecular picture of relapsed, refractory, metastatic or advanced cancers. With an extensive analysis of approximately 20,000 genes, OncoExTra is one of the most comprehensive genomic profiling assays. By interrogating both the whole exome (DNA) and whole transcriptome (RNA), OncoExTra provides vital information regarding both treatment and available clinical trials.⁵

Driving innovation through our pipeline

Building on the success of the Cologuard and Oncotype DX tests, the company is investing in its product pipeline across the cancer continuum. A multi-cancer early detection (MCED) blood test in development has the potential to make routine screening for multiple types of cancer a reality. We are also developing solutions for molecular residual disease (MRD) testing that may help discover cancer recurrence earlier. We are collaborating with Mayo Clinic, Johns Hopkins University, and The Translational Genomics Research Institute (an affiliate of City of Hope) to develop a pipeline of new cancer detection tests. Using proprietary DNA chemistry and the flexible automated laboratory platform, we aim to develop blood-based cancer tests that empower the detection of cancers in their earliest, most treatable stages.

Please visit the company's website [exactsciences.com](https://www.exactsciences.com) and follow Exact Sciences on X (formerly Twitter), Facebook and LinkedIn.

Sources

1. Sung, H, Ferlay, J, Siegel, RL, Laversanne, M, Soerjomataram, I, Jemal, A, Bray, F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021; 71: 209- 249.
2. Internal Data on File. Exact Sciences Corporation. Madison, Wisconsin.
3. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med.* 2014;370(14):1287-1297.
4. Chalasani NP, Porter K, Bhattacharya A, et al. Validation of a novel multi-target blood test shows high sensitivity to detect early-stage hepatocellular carcinoma. *Clin Gastroenterol Hepatol.* 2022;20:173-182.
5. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. *Sci Transl Med.* 2015;7(283):283ra53.

**EXACT
SCIENCES**

Cologuard, Oncoguard, Riskguard and Exact Sciences are trademarks of Exact Sciences Corporation.

Oncotype, Oncotype DX, and OncoExTra are trademarks of Genomic Health, Inc., a wholly owned subsidiary of Exact Sciences Corporation. All other trademarks are the properties of their respective owners.

© 2023 Exact Sciences Corporation. All rights reserved. M-US-ES-00530.